JP6872532B2 - 腸外病原性大腸菌に対する免疫防御のための方法および組成物 - Google Patents

腸外病原性大腸菌に対する免疫防御のための方法および組成物 Download PDF

Info

Publication number
JP6872532B2
JP6872532B2 JP2018510886A JP2018510886A JP6872532B2 JP 6872532 B2 JP6872532 B2 JP 6872532B2 JP 2018510886 A JP2018510886 A JP 2018510886A JP 2018510886 A JP2018510886 A JP 2018510886A JP 6872532 B2 JP6872532 B2 JP 6872532B2
Authority
JP
Japan
Prior art keywords
coli
antigen
composition
escherichia coli
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525423A (ja
JP2018525423A5 (cg-RX-API-DMAC7.html
Inventor
プールマン，ヤン，トゥーニス
ジャックミン，バート
アッバナット，ダレン，ロバート
ヨン，パトリシア，イバッラ
ハーマンス，ピーター，ウィルヘルムス，マリア
コワリク，ミヒャエル，トーマス
ヴェッター，ミヒャエル，ルーカス
ケムラー，ステファン，ヨッヘン
ハウプトル，ミヒャ，アンドレス
ガンビッラーラ，ヴェロニカ
マリー，マヌエラ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
ヤンセン ファーマシューティカルズ，インコーポレーテッド
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, ヤンセン ファーマシューティカルズ，インコーポレーテッド, ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2018525423A publication Critical patent/JP2018525423A/ja
Publication of JP2018525423A5 publication Critical patent/JP2018525423A5/ja
Application granted granted Critical
Publication of JP6872532B2 publication Critical patent/JP6872532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018510886A 2015-08-24 2016-08-24 腸外病原性大腸菌に対する免疫防御のための方法および組成物 Active JP6872532B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209091P 2015-08-24 2015-08-24
US62/209,091 2015-08-24
US201562210655P 2015-08-27 2015-08-27
US62/210,655 2015-08-27
PCT/US2016/048278 WO2017035181A1 (en) 2015-08-24 2016-08-24 Methods and compositions for immune protection against extra-intestinal pathogenic e. coli

Publications (3)

Publication Number Publication Date
JP2018525423A JP2018525423A (ja) 2018-09-06
JP2018525423A5 JP2018525423A5 (cg-RX-API-DMAC7.html) 2019-10-03
JP6872532B2 true JP6872532B2 (ja) 2021-05-19

Family

ID=56855827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510886A Active JP6872532B2 (ja) 2015-08-24 2016-08-24 腸外病原性大腸菌に対する免疫防御のための方法および組成物

Country Status (18)

Country Link
US (3) US10583185B2 (cg-RX-API-DMAC7.html)
EP (2) EP3341016B9 (cg-RX-API-DMAC7.html)
JP (1) JP6872532B2 (cg-RX-API-DMAC7.html)
KR (1) KR102735147B1 (cg-RX-API-DMAC7.html)
CN (1) CN108430500B (cg-RX-API-DMAC7.html)
AU (1) AU2016312422B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003469A2 (cg-RX-API-DMAC7.html)
EA (1) EA037500B1 (cg-RX-API-DMAC7.html)
ES (1) ES2951408T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230947T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063961T2 (cg-RX-API-DMAC7.html)
IL (1) IL257608B (cg-RX-API-DMAC7.html)
MX (1) MX2018002340A (cg-RX-API-DMAC7.html)
PL (1) PL3341016T3 (cg-RX-API-DMAC7.html)
RS (1) RS64449B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300220T1 (cg-RX-API-DMAC7.html)
TW (1) TWI715617B (cg-RX-API-DMAC7.html)
WO (1) WO2017035181A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536884T1 (de) * 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
IL273685B2 (en) 2013-01-17 2023-10-01 X4 Pharmaceuticals Austria Gmbh Immunogens and vaccines containing O25b antigens
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
UY38616A (es) * 2019-03-18 2020-09-30 Janssen Pharmaceuticals Inc Bioconjugados de polisacáridos del antígeno-o de e. coli y métodos de producción y de uso de los mismos.
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
PL4090363T3 (pl) 2020-01-16 2024-11-25 Janssen Pharmaceuticals, Inc. Mutant fimh, jego kompozycje i jego zastosowanie
MX2022010350A (es) * 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
WO2021219530A1 (en) 2020-04-28 2021-11-04 Janssen Pharmaceuticals, Inc. Method for identification and quantification of polysaccharides in complex glycoconjugate compositions
CA3185642A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
ES3030259T3 (en) * 2020-11-30 2025-06-27 Janssen Pharmaceuticals Inc Analytical method for glycoconjugates using a capillary-based immunoassay system
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
US20220236283A1 (en) * 2021-01-28 2022-07-28 Janssen Pharmaceuticals, Inc. Method for identification and quantification of polysaccharides in complex glycoconjugate compositions
US12491237B2 (en) 2021-02-16 2025-12-09 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
WO2022214620A1 (en) 2021-04-08 2022-10-13 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
AR131046A1 (es) * 2022-11-15 2025-02-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y sus usos
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods
CN118286407B (zh) * 2024-04-08 2025-04-01 江西省农业科学院畜牧兽医研究所 一种禽大肠杆菌病三价灭活疫苗及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
AU2001253568A1 (en) 2000-04-18 2001-10-30 Dan C. Deborde Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
WO2005095450A2 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
AU2005243548A1 (en) * 2004-05-14 2005-11-24 National Research Council Canada Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
CN101360831B (zh) 2005-05-11 2013-07-10 Eth苏黎世公司 来自原核细胞的重组n-糖基化蛋白
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
SG10201400320TA (en) * 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
EP3461840A1 (en) 2009-04-27 2019-04-03 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
WO2011062615A1 (en) 2009-11-19 2011-05-26 Glycovaxyn Ag Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
JP2014502595A (ja) 2010-12-10 2014-02-03 メルク・シャープ・アンド・ドーム・コーポレーション 免疫原性組成物の撹拌誘導凝集を緩和する新規な製剤
CA2847621A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
HK1212249A1 (en) * 2012-09-10 2016-06-10 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
EP2906681B1 (en) 2012-10-12 2019-01-09 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
EP2938363B1 (en) 2012-12-27 2019-08-21 GlaxoSmithKline Biologicals S.A. Methods and compositions relating to crm197
IL273685B2 (en) 2013-01-17 2023-10-01 X4 Pharmaceuticals Austria Gmbh Immunogens and vaccines containing O25b antigens
BR112016007727A8 (pt) 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
CA2935532A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
HUE057726T2 (hu) 2014-12-30 2022-06-28 Glaxosmithkline Biologicals Sa Fehérje glikozilálására szolgáló készítmények és módszerek
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
UY38616A (es) 2019-03-18 2020-09-30 Janssen Pharmaceuticals Inc Bioconjugados de polisacáridos del antígeno-o de e. coli y métodos de producción y de uso de los mismos.
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef

Also Published As

Publication number Publication date
US20230062987A1 (en) 2023-03-02
NZ739963A (en) 2024-02-23
EP3341016A1 (en) 2018-07-04
JP2018525423A (ja) 2018-09-06
EA201890400A1 (ru) 2018-09-28
US10583185B2 (en) 2020-03-10
PL3341016T3 (pl) 2023-11-13
US12076385B2 (en) 2024-09-03
ES2951408T3 (es) 2023-10-20
AU2016312422A1 (en) 2018-03-29
IL257608B (en) 2021-12-01
EA037500B1 (ru) 2021-04-05
BR112018003469A2 (pt) 2018-09-25
HRP20230947T1 (hr) 2023-11-24
EP3341016C0 (en) 2023-06-07
TWI715617B (zh) 2021-01-11
CN108430500B (zh) 2021-12-24
EP3341016B9 (en) 2023-09-27
CN108430500A (zh) 2018-08-21
HUE063961T2 (hu) 2024-02-28
KR102735147B1 (ko) 2024-11-26
US20180243393A1 (en) 2018-08-30
TW201714620A (zh) 2017-05-01
MX2018002340A (es) 2018-09-17
US11484582B2 (en) 2022-11-01
US20210046171A1 (en) 2021-02-18
AU2016312422B2 (en) 2019-09-26
SMT202300220T1 (it) 2023-09-06
CA2995873A1 (en) 2017-03-02
WO2017035181A1 (en) 2017-03-02
EP4245320A2 (en) 2023-09-20
KR20180054629A (ko) 2018-05-24
IL257608A (en) 2018-04-30
EP4245320A3 (en) 2023-11-22
EP3341016B1 (en) 2023-06-07
RS64449B1 (sr) 2023-09-29

Similar Documents

Publication Publication Date Title
JP6872532B2 (ja) 腸外病原性大腸菌に対する免疫防御のための方法および組成物
Cohen et al. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
TWI815860B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物
CN1306958C (zh) 用于免疫受损人群的糖结合物疫苗
TWI826420B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物
US20090098157A1 (en) Helicobacter Pylori Vaccination
TW201946650A (zh) 針對腹內感染之疫苗
JP2021522213A (ja) ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体
US20180271969A1 (en) Streptococcus suis polysaccharide-protein conjugate composition
JP2020525495A (ja) 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
Kaplonek et al. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae
US9616116B2 (en) Detoxified endotoxin immunogenic compositions and uses thereof
HK40101369A (en) Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
CA2995873C (en) Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
US20090220522A1 (en) Detoxified Endotoxin Vaccine and Adjuvant and Uses thereof
Kassab Development of lipid nanoparticles (LNP)-RNA vaccine against Streptococcus pneumoniae gene cluster facilitating the synthesis of the capsular polysaccharide in Egypt.
WO2025224732A1 (en) Meningococcal hexavalent combination vaccine
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
Lucero et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with...
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20181026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210419

R150 Certificate of patent or registration of utility model

Ref document number: 6872532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250